CI

At a glance

ClinicalIndex Comparison Record
Phase 4Completed· 72 enrolled
Drug / intervention
Morphine Sulfatedrug
Likely dose
Not stated in record
Structured eligibility isn't available for this trial yet — see the full criteria in the Eligibility tab below.

Standardized by ClinicalIndex from the ClinicalTrials.gov record · verify against the source.

Search/NCT05069012
NCT05069012Phase 4Completed
CompareCT.gov

Optimal Dose of Intrathecal Morphine for Postoperative Analgesia After Cesarean Delivery

Beth Israel Deaconess Medical Center·interventional·Posted Oct 6, 2021·Updated Nov 13, 2025

In Brief

A Phase 4 clinical trial evaluating Morphine Sulfate for Postoperative Pain. Completed, enrolled 72 participants across 1 site.

Detailed Summary

This is a randomized double blinded non-inferiority study comparing the duration of pain relief when patients receive one of three doses of spinal morphine. Enrolled patients will be randomly assigned to receive either 50 mcg, 150 mcg, or 250 mcg. All patients will receive standardized postoperative care, including multimodal analgesia. The primary outcome will be the time until the patient requests additional opioid pain medications.

Study Details

Study Typeinterventional
Allocation--
Masking--
Primary Purpose--
ConditionsPostoperative Pain
CountriesUnited States
Collaborators--

Timeline

Phase 4CompletedFinished
20222023202420252026
First PostedOct 6, 2021
Enrollment StartNov 15, 2021
Primary CompletionJul 23, 2022
TodayJul 2, 2026
Enrollment to primary: 8 monthsPosted 4.7 years ago

Interventions

Morphine Sulfatedrug

Morphine is administered to provide pain relief after cesarean delivery; this is an assessment of the dose-response as measured by the duration of pain relief